-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
2021 is fleeting, and in the past year, A shares have set multiple records
.
In terms of pharmaceutical stocks, the Chinese medicine sector performed brightly on the last trading day of last year, rising by more than 5%, and more than 10 Chinese medicine stocks such as Taiji Group and Qianjin Pharmaceutical rose by the daily limit
.
As of the close on December 31, 2021, 14 pharmaceutical stocks including Mindray Medical, WuXi AppTec, Hengrui Medicine, and Pien Tze Huang have a market value of 100 billion yuan
.
Mindray Medical ranked as the "first brother" of pharmaceutical stocks, and BeiGene entered the top ten; Pien Tze Huang rose to the fourth place with a growth rate of more than 60%, and its market value reached a new high
.
Judging from the rise and fall, the market value of 48 companies including Guangyuyuan and Medicilon has doubled
.
It is worth mentioning that in 2019, there were only 5 pharmaceutical stocks with a market value of 100 billion yuan, which will surge to 11 in 2020
.
.
In terms of pharmaceutical stocks, the Chinese medicine sector performed brightly on the last trading day of last year, rising by more than 5%, and more than 10 Chinese medicine stocks such as Taiji Group and Qianjin Pharmaceutical rose by the daily limit
.
As of the close on December 31, 2021, 14 pharmaceutical stocks including Mindray Medical, WuXi AppTec, Hengrui Medicine, and Pien Tze Huang have a market value of 100 billion yuan
.
Mindray Medical ranked as the "first brother" of pharmaceutical stocks, and BeiGene entered the top ten; Pien Tze Huang rose to the fourth place with a growth rate of more than 60%, and its market value reached a new high
.
Judging from the rise and fall, the market value of 48 companies including Guangyuyuan and Medicilon has doubled
.
It is worth mentioning that in 2019, there were only 5 pharmaceutical stocks with a market value of 100 billion yuan, which will surge to 11 in 2020
.
The "first brother" of the pharmaceutical stocks flashed over 40 billion, and the Chinese medicine stocks went up and down
On the first day of the opening of the A-share market in 2022 (January 4th), Mindray Medical, the “first brother” of the pharmaceutical stock, suddenly crashed in the intraday market
.
According to the news, there are rumors in the market that Mindray Medical's performance did not meet expectations, and sales staff left in large numbers
.
In response, Mindray Medical responded that the company has not disclosed its 2021 annual report, so it cannot disclose performance-related situations
.
The company has not released any relevant information affecting the performance trend, and there has been no incident where the performance did not meet expectations and the sales staff left
.
.
According to the news, there are rumors in the market that Mindray Medical's performance did not meet expectations, and sales staff left in large numbers
.
In response, Mindray Medical responded that the company has not disclosed its 2021 annual report, so it cannot disclose performance-related situations
.
The company has not released any relevant information affecting the performance trend, and there has been no incident where the performance did not meet expectations and the sales staff left
.
According to the data, Mindray Medical's revenue in the first three quarters of 2021 was 19.
392 billion yuan, a year-on-year increase of 20.
72%; its net profit was 6.
663 billion yuan, a year-on-year increase of 24.
23%
.
As of the close on January 5, Mindray Medical's share price rose by more than 3%, with a market value of nearly 420 billion yuan
.
392 billion yuan, a year-on-year increase of 20.
72%; its net profit was 6.
663 billion yuan, a year-on-year increase of 24.
23%
.
As of the close on January 5, Mindray Medical's share price rose by more than 3%, with a market value of nearly 420 billion yuan
.
Note: Statistics as of the close of market on January 4, 2022
On the last trading day of 2021, the traditional Chinese medicine sector rose by more than 5%, and more than 10 traditional Chinese medicine stocks, including Zuoli Pharmaceutical, Taiji Group, Tongrentang, Jianmin Group, and Qianjin Pharmaceutical, reached the daily limit
.
On the first day of trading in 2022, although the three major indexes fell across the board, Chinese medicine stocks bucked the trend and strengthened.
As of the close of the day, more than 10 Chinese medicine stocks, including Taiji Group, Qianjin Pharmaceutical, and Yisheng Pharmaceutical, continued to trade at their daily limit.
Among them, Tongrentang and Jianmin Group wait for new highs
.
Judging from the news, recently, the National Medical Security Administration and the State Administration of Traditional Chinese Medicine issued the "Guiding Opinions on Medical Insurance Supporting the Inheritance and Innovation of Traditional Chinese Medicine"; Approved to build a national comprehensive reform demonstration area of traditional Chinese medicine
.
.
On the first day of trading in 2022, although the three major indexes fell across the board, Chinese medicine stocks bucked the trend and strengthened.
As of the close of the day, more than 10 Chinese medicine stocks, including Taiji Group, Qianjin Pharmaceutical, and Yisheng Pharmaceutical, continued to trade at their daily limit.
Among them, Tongrentang and Jianmin Group wait for new highs
.
Judging from the news, recently, the National Medical Security Administration and the State Administration of Traditional Chinese Medicine issued the "Guiding Opinions on Medical Insurance Supporting the Inheritance and Innovation of Traditional Chinese Medicine"; Approved to build a national comprehensive reform demonstration area of traditional Chinese medicine
.
On January 1, 2022, Taiji Group released the "14th Five-Year" Strategic Planning Outline (2021-2025), which clarified that the main line of intelligent manufacturing of modern traditional Chinese medicine, supplemented by the characteristic chemical drugs of anesthesia and regional commercial leaders the strategic direction of the line
.
The core main line gives full play to the brand influence of the well-known trademark of "Taiji (TAIJI)" and the century-old "Tongjunge" brand, fully taps the market value of traditional Chinese medicine, brand products, and classic prescriptions, and creates a variety of products with technological innovation, intelligent manufacturing, etc.
Advantages of modern Chinese medicine
.
The parallel auxiliary line is to build a chemical and biological drug production base featuring narcotics and to build a leading pharmaceutical business enterprise in Sichuan and Chongqing
.
The company unswervingly focuses on the main business of medicine and health, and on the premise of steady improvement in basic management, realizes the "achievement of scientific research and development capabilities, source control, production intelligence, terminal connection and marketing breakthrough, and creating new models, new formats and new concepts.
" The large-scale pharmaceutical base in the “Chongqing Shuangcheng Circle” has become the strategic growth pole of Sinopharm Group in western China
.
Through endogenous development and external expansion, the company strives to achieve a revenue of 50 billion yuan at the end of the "14th Five-Year Plan", and strives to become a world-class Chinese medicine enterprise
.
.
The core main line gives full play to the brand influence of the well-known trademark of "Taiji (TAIJI)" and the century-old "Tongjunge" brand, fully taps the market value of traditional Chinese medicine, brand products, and classic prescriptions, and creates a variety of products with technological innovation, intelligent manufacturing, etc.
Advantages of modern Chinese medicine
.
The parallel auxiliary line is to build a chemical and biological drug production base featuring narcotics and to build a leading pharmaceutical business enterprise in Sichuan and Chongqing
.
The company unswervingly focuses on the main business of medicine and health, and on the premise of steady improvement in basic management, realizes the "achievement of scientific research and development capabilities, source control, production intelligence, terminal connection and marketing breakthrough, and creating new models, new formats and new concepts.
" The large-scale pharmaceutical base in the “Chongqing Shuangcheng Circle” has become the strategic growth pole of Sinopharm Group in western China
.
Through endogenous development and external expansion, the company strives to achieve a revenue of 50 billion yuan at the end of the "14th Five-Year Plan", and strives to become a world-class Chinese medicine enterprise
.
Looking back on last year, the pharmaceutical sector as a whole showed a first rise and then a decline.
Since November, the sector index has started to repair again, and since late December, the traditional Chinese medicine sector has continued to strengthen
.
The brokerage analysis pointed out that the country has successively introduced relevant policies for the development of the Chinese medicine industry in recent years, and incorporated Chinese medicine into the national development plan.
Good for the long-term development of the industry
.
Since November, the sector index has started to repair again, and since late December, the traditional Chinese medicine sector has continued to strengthen
.
The brokerage analysis pointed out that the country has successively introduced relevant policies for the development of the Chinese medicine industry in recent years, and incorporated Chinese medicine into the national development plan.
Good for the long-term development of the industry
.
Top 20 pharmaceutical stocks
Note: Statistics as of the close of business on December 31, 2021
According to statistics, 14 pharmaceutical stocks, including Mindray Medical, WuXi AppTec, Hengrui Pharmaceutical, Pien Tze Huang, and BeiGene, are worth 100 billion yuan
.
Mindray Medical was listed as the "first brother" in pharmaceutical stocks, and BeiGene entered the top ten as the first "A+H+N" listed pharmaceutical company
.
Pien Tze Huang ranked 4th with a growth rate of more than 60%, up 3 places compared with 2020, and is also the fastest growing company in the TOP20
.
In addition, the market value growth rate of Wantai Bio and Huadong Medicine both exceeded 50%
.
It is worth mentioning that in 2019, there were only 5 pharmaceutical stocks with a market value of 100 billion yuan, which will surge to 11 in 2020
.
.
Mindray Medical was listed as the "first brother" in pharmaceutical stocks, and BeiGene entered the top ten as the first "A+H+N" listed pharmaceutical company
.
Pien Tze Huang ranked 4th with a growth rate of more than 60%, up 3 places compared with 2020, and is also the fastest growing company in the TOP20
.
In addition, the market value growth rate of Wantai Bio and Huadong Medicine both exceeded 50%
.
It is worth mentioning that in 2019, there were only 5 pharmaceutical stocks with a market value of 100 billion yuan, which will surge to 11 in 2020
.
The strongest "demon stock" in the fourth quarter was born! Guangyuyuan, Jianmin.
.
.
The market value of 48 companies doubled
.
.
The market value of 48 companies doubled
Pharmaceutical stocks that rose more than 100%
Note: Statistics as of the close of business on December 31, 2021
From the perspective of changes, the market value of 48 companies including Guangyuyuan, Medicilon, Jianmin Group, Shuyu Pingmin, and Ha Sanlian has doubled.
Among them, Jiu'an Medical has achieved 24 daily limits in 34 trading days, becoming the fourth The strongest "demon stock" in the quarter; Longshen Rongfa soared 140% in 9 trading days and was suspended for verification
.
Among them, Jiu'an Medical has achieved 24 daily limits in 34 trading days, becoming the fourth The strongest "demon stock" in the quarter; Longshen Rongfa soared 140% in 9 trading days and was suspended for verification
.
Jiu'an Medical started the rising mode in mid-November 2021.
From November 15th to now, it has gained 24 daily limits in 34 trading days, with an increase of more than 400% in 2021
.
During this period, the company issued a number of abnormal stock trading fluctuations and risk warning announcements, letters of concern, and supervision letters, but this did not suppress the continuous rise of Jiu'an Medical's stock price
.
On December 30, Jiu’an Medical released the company’s stock trading risk warning announcement, saying that the company mentioned in the previous announcement the epidemic prevention-related plans issued by the U.
S.
government, as well as the relevant policies, procurement and distribution of the new crown antigen home self-test kit products.
plans and situations
.
Investors are advised to note that the relevant situations and purchases involved in the above content are not just for the company.
Do not misunderstand the content and wrongly infer the changes it will bring to the company's performance
.
The sales situation disclosed by the company in the previous announcement cannot represent the profit.
Because the profit is related to many factors such as raw material cost, sales expenses, management expenses and R&D expenses, it is impossible to calculate the profit situation from the sales amount.
The company's stock price is currently at a historical high.
The risk of a fall in the future cannot be ruled out
.
On the last trading day of 2021, Jiu'an Medical's stock price fell by the limit.
Even if it fell sharply, the company still ranked 4th on the increase list with its strong previous gains
.
From November 15th to now, it has gained 24 daily limits in 34 trading days, with an increase of more than 400% in 2021
.
During this period, the company issued a number of abnormal stock trading fluctuations and risk warning announcements, letters of concern, and supervision letters, but this did not suppress the continuous rise of Jiu'an Medical's stock price
.
On December 30, Jiu’an Medical released the company’s stock trading risk warning announcement, saying that the company mentioned in the previous announcement the epidemic prevention-related plans issued by the U.
S.
government, as well as the relevant policies, procurement and distribution of the new crown antigen home self-test kit products.
plans and situations
.
Investors are advised to note that the relevant situations and purchases involved in the above content are not just for the company.
Do not misunderstand the content and wrongly infer the changes it will bring to the company's performance
.
The sales situation disclosed by the company in the previous announcement cannot represent the profit.
Because the profit is related to many factors such as raw material cost, sales expenses, management expenses and R&D expenses, it is impossible to calculate the profit situation from the sales amount.
The company's stock price is currently at a historical high.
The risk of a fall in the future cannot be ruled out
.
On the last trading day of 2021, Jiu'an Medical's stock price fell by the limit.
Even if it fell sharply, the company still ranked 4th on the increase list with its strong previous gains
.
Recently, Longshen Rongfa also hit the daily limit again, rising 140% in 9 trading days
.
On December 31, the company issued an announcement of serious abnormal fluctuations in stock trading and suspension of trading
.
According to the data, the main business of Longshen Rongfa is the research and development of pharmaceutical products, medical products, and health care products, and the production and sales of Chinese patent medicines, health food, and APIs
.
The main products Yuanhu Zhitong Dropping Pills, Suanzaoren Oil Dropping Pills, Berberine Tannic Acid Film and Qiwei Wenyang Capsules are all exclusive varieties
.
In the first three quarters of 2021, the company's revenue was 167 million yuan, a year-on-year decrease of 0.
75%; net profit loss was 8.
18 million yuan, a year-on-year increase of 35.
84%; gross profit margin was 29.
23%
.
.
On December 31, the company issued an announcement of serious abnormal fluctuations in stock trading and suspension of trading
.
According to the data, the main business of Longshen Rongfa is the research and development of pharmaceutical products, medical products, and health care products, and the production and sales of Chinese patent medicines, health food, and APIs
.
The main products Yuanhu Zhitong Dropping Pills, Suanzaoren Oil Dropping Pills, Berberine Tannic Acid Film and Qiwei Wenyang Capsules are all exclusive varieties
.
In the first three quarters of 2021, the company's revenue was 167 million yuan, a year-on-year decrease of 0.
75%; net profit loss was 8.
18 million yuan, a year-on-year increase of 35.
84%; gross profit margin was 29.
23%
.
Source: Oriental Fortune Network, company announcement
2021 is fleeting, and in the past year, A shares have set multiple records
.
In terms of pharmaceutical stocks, the Chinese medicine sector performed brightly on the last trading day of last year, rising by more than 5%, and more than 10 Chinese medicine stocks such as Taiji Group and Qianjin Pharmaceutical rose by the daily limit
.
As of the close on December 31, 2021, 14 pharmaceutical stocks including Mindray Medical, WuXi AppTec, Hengrui Medicine, and Pien Tze Huang have a market value of 100 billion yuan
.
Mindray Medical ranked as the "first brother" of pharmaceutical stocks, and BeiGene entered the top ten; Pien Tze Huang rose to the fourth place with a growth rate of more than 60%, and its market value reached a new high
.
Judging from the rise and fall, the market value of 48 companies including Guangyuyuan and Medicilon has doubled
.
It is worth mentioning that in 2019, there were only 5 pharmaceutical stocks with a market value of 100 billion yuan, which will surge to 11 in 2020
.
.
In terms of pharmaceutical stocks, the Chinese medicine sector performed brightly on the last trading day of last year, rising by more than 5%, and more than 10 Chinese medicine stocks such as Taiji Group and Qianjin Pharmaceutical rose by the daily limit
.
As of the close on December 31, 2021, 14 pharmaceutical stocks including Mindray Medical, WuXi AppTec, Hengrui Medicine, and Pien Tze Huang have a market value of 100 billion yuan
.
Mindray Medical ranked as the "first brother" of pharmaceutical stocks, and BeiGene entered the top ten; Pien Tze Huang rose to the fourth place with a growth rate of more than 60%, and its market value reached a new high
.
Judging from the rise and fall, the market value of 48 companies including Guangyuyuan and Medicilon has doubled
.
It is worth mentioning that in 2019, there were only 5 pharmaceutical stocks with a market value of 100 billion yuan, which will surge to 11 in 2020
.
The "first brother" of the pharmaceutical stocks flashed over 40 billion, and the Chinese medicine stocks went up and down
On the first day of the opening of the A-share market in 2022 (January 4th), Mindray Medical, the “first brother” of the pharmaceutical stock, suddenly crashed in the intraday market
.
According to the news, there are rumors in the market that Mindray Medical's performance did not meet expectations, and sales staff left in large numbers
.
In response, Mindray Medical responded that the company has not disclosed its 2021 annual report, so it cannot disclose performance-related situations
.
The company has not released any relevant information affecting the performance trend, and there has been no incident where the performance did not meet expectations and the sales staff left
.
.
According to the news, there are rumors in the market that Mindray Medical's performance did not meet expectations, and sales staff left in large numbers
.
In response, Mindray Medical responded that the company has not disclosed its 2021 annual report, so it cannot disclose performance-related situations
.
The company has not released any relevant information affecting the performance trend, and there has been no incident where the performance did not meet expectations and the sales staff left
.
According to the data, Mindray Medical's revenue in the first three quarters of 2021 was 19.
392 billion yuan, a year-on-year increase of 20.
72%; its net profit was 6.
663 billion yuan, a year-on-year increase of 24.
23%
.
As of the close on January 5, Mindray Medical's share price rose by more than 3%, with a market value of nearly 420 billion yuan
.
392 billion yuan, a year-on-year increase of 20.
72%; its net profit was 6.
663 billion yuan, a year-on-year increase of 24.
23%
.
As of the close on January 5, Mindray Medical's share price rose by more than 3%, with a market value of nearly 420 billion yuan
.
Note: Statistics as of the close of market on January 4, 2022
On the last trading day of 2021, the traditional Chinese medicine sector rose by more than 5%, and more than 10 traditional Chinese medicine stocks, including Zuoli Pharmaceutical, Taiji Group, Tongrentang, Jianmin Group, and Qianjin Pharmaceutical, reached the daily limit
.
On the first day of trading in 2022, although the three major indexes fell across the board, Chinese medicine stocks bucked the trend and strengthened.
As of the close of the day, more than 10 Chinese medicine stocks, including Taiji Group, Qianjin Pharmaceutical, and Yisheng Pharmaceutical, continued to trade at their daily limit.
Among them, Tongrentang and Jianmin Group wait for new highs
.
Judging from the news, recently, the National Medical Security Administration and the State Administration of Traditional Chinese Medicine issued the "Guiding Opinions on Medical Insurance Supporting the Inheritance and Innovation of Traditional Chinese Medicine"; Approved to build a national comprehensive reform demonstration area of traditional Chinese medicine
.
.
On the first day of trading in 2022, although the three major indexes fell across the board, Chinese medicine stocks bucked the trend and strengthened.
As of the close of the day, more than 10 Chinese medicine stocks, including Taiji Group, Qianjin Pharmaceutical, and Yisheng Pharmaceutical, continued to trade at their daily limit.
Among them, Tongrentang and Jianmin Group wait for new highs
.
Judging from the news, recently, the National Medical Security Administration and the State Administration of Traditional Chinese Medicine issued the "Guiding Opinions on Medical Insurance Supporting the Inheritance and Innovation of Traditional Chinese Medicine"; Approved to build a national comprehensive reform demonstration area of traditional Chinese medicine
.
On January 1, 2022, Taiji Group released the "14th Five-Year" Strategic Planning Outline (2021-2025), which clarified that the main line of intelligent manufacturing of modern traditional Chinese medicine, supplemented by the characteristic chemical drugs of anesthesia and regional commercial leaders the strategic direction of the line
.
The core main line gives full play to the brand influence of the well-known trademark of "Taiji (TAIJI)" and the century-old "Tongjunge" brand, fully taps the market value of traditional Chinese medicine, brand products, and classic prescriptions, and creates a variety of products with technological innovation, intelligent manufacturing, etc.
Advantages of modern Chinese medicine
.
The parallel auxiliary line is to build a chemical and biological drug production base featuring narcotics and to build a leading pharmaceutical business enterprise in Sichuan and Chongqing
.
The company unswervingly focuses on the main business of medicine and health, and on the premise of steady improvement in basic management, realizes the "achievement of scientific research and development capabilities, source control, production intelligence, terminal connection and marketing breakthrough, and creating new models, new formats and new concepts.
" The large-scale pharmaceutical base in the “Chongqing Shuangcheng Circle” has become the strategic growth pole of Sinopharm Group in western China
.
Through endogenous development and external expansion, the company strives to achieve a revenue of 50 billion yuan at the end of the "14th Five-Year Plan", and strives to become a world-class Chinese medicine enterprise
.
.
The core main line gives full play to the brand influence of the well-known trademark of "Taiji (TAIJI)" and the century-old "Tongjunge" brand, fully taps the market value of traditional Chinese medicine, brand products, and classic prescriptions, and creates a variety of products with technological innovation, intelligent manufacturing, etc.
Advantages of modern Chinese medicine
.
The parallel auxiliary line is to build a chemical and biological drug production base featuring narcotics and to build a leading pharmaceutical business enterprise in Sichuan and Chongqing
.
The company unswervingly focuses on the main business of medicine and health, and on the premise of steady improvement in basic management, realizes the "achievement of scientific research and development capabilities, source control, production intelligence, terminal connection and marketing breakthrough, and creating new models, new formats and new concepts.
" The large-scale pharmaceutical base in the “Chongqing Shuangcheng Circle” has become the strategic growth pole of Sinopharm Group in western China
.
Through endogenous development and external expansion, the company strives to achieve a revenue of 50 billion yuan at the end of the "14th Five-Year Plan", and strives to become a world-class Chinese medicine enterprise
.
Looking back on last year, the pharmaceutical sector as a whole showed a first rise and then a decline.
Since November, the sector index has started to repair again, and since late December, the traditional Chinese medicine sector has continued to strengthen
.
The brokerage analysis pointed out that the country has successively introduced relevant policies for the development of the Chinese medicine industry in recent years, and incorporated Chinese medicine into the national development plan.
Good for the long-term development of the industry
.
Since November, the sector index has started to repair again, and since late December, the traditional Chinese medicine sector has continued to strengthen
.
The brokerage analysis pointed out that the country has successively introduced relevant policies for the development of the Chinese medicine industry in recent years, and incorporated Chinese medicine into the national development plan.
Good for the long-term development of the industry
.
Top 20 pharmaceutical stocks
Note: Statistics as of the close of business on December 31, 2021
According to statistics, 14 pharmaceutical stocks, including Mindray Medical, WuXi AppTec, Hengrui Pharmaceutical, Pien Tze Huang, and BeiGene, are worth 100 billion yuan
.
Mindray Medical was listed as the "first brother" in pharmaceutical stocks, and BeiGene entered the top ten as the first "A+H+N" listed pharmaceutical company
.
Pien Tze Huang ranked 4th with a growth rate of more than 60%, up 3 places compared with 2020, and is also the fastest growing company in the TOP20
.
In addition, the market value growth rate of Wantai Bio and Huadong Medicine both exceeded 50%
.
It is worth mentioning that in 2019, there were only 5 pharmaceutical stocks with a market value of 100 billion yuan, which will surge to 11 in 2020
.
.
Mindray Medical was listed as the "first brother" in pharmaceutical stocks, and BeiGene entered the top ten as the first "A+H+N" listed pharmaceutical company
.
Pien Tze Huang ranked 4th with a growth rate of more than 60%, up 3 places compared with 2020, and is also the fastest growing company in the TOP20
.
In addition, the market value growth rate of Wantai Bio and Huadong Medicine both exceeded 50%
.
It is worth mentioning that in 2019, there were only 5 pharmaceutical stocks with a market value of 100 billion yuan, which will surge to 11 in 2020
.
The strongest "demon stock" in the fourth quarter was born! Guangyuyuan, Jianmin.
.
.
The market value of 48 companies doubled
.
.
The market value of 48 companies doubled
Pharmaceutical stocks that rose more than 100%
Note: Statistics as of the close of business on December 31, 2021
From the perspective of changes, the market value of 48 companies including Guangyuyuan, Medicilon, Jianmin Group, Shuyu Pingmin, and Ha Sanlian has doubled.
Among them, Jiu'an Medical has achieved 24 daily limits in 34 trading days, becoming the fourth The strongest "demon stock" in the quarter; Longshen Rongfa soared 140% in 9 trading days and was suspended for verification
.
Among them, Jiu'an Medical has achieved 24 daily limits in 34 trading days, becoming the fourth The strongest "demon stock" in the quarter; Longshen Rongfa soared 140% in 9 trading days and was suspended for verification
.
Jiu'an Medical started the rising mode in mid-November 2021.
From November 15th to now, it has gained 24 daily limits in 34 trading days, with an increase of more than 400% in 2021
.
During this period, the company issued a number of abnormal stock trading fluctuations and risk warning announcements, letters of concern, and supervision letters, but this did not suppress the continuous rise of Jiu'an Medical's stock price
.
On December 30, Jiu’an Medical released the company’s stock trading risk warning announcement, saying that the company mentioned in the previous announcement the epidemic prevention-related plans issued by the U.
S.
government, as well as the relevant policies, procurement and distribution of the new crown antigen home self-test kit products.
plans and situations
.
Investors are advised to note that the relevant situations and purchases involved in the above content are not just for the company.
Do not misunderstand the content and wrongly infer the changes it will bring to the company's performance
.
The sales situation disclosed by the company in the previous announcement cannot represent the profit.
Because the profit is related to many factors such as raw material cost, sales expenses, management expenses and R&D expenses, it is impossible to calculate the profit situation from the sales amount.
The company's stock price is currently at a historical high.
The risk of a fall in the future cannot be ruled out
.
On the last trading day of 2021, Jiu'an Medical's stock price fell by the limit.
Even if it fell sharply, the company still ranked 4th on the increase list with its strong previous gains
.
From November 15th to now, it has gained 24 daily limits in 34 trading days, with an increase of more than 400% in 2021
.
During this period, the company issued a number of abnormal stock trading fluctuations and risk warning announcements, letters of concern, and supervision letters, but this did not suppress the continuous rise of Jiu'an Medical's stock price
.
On December 30, Jiu’an Medical released the company’s stock trading risk warning announcement, saying that the company mentioned in the previous announcement the epidemic prevention-related plans issued by the U.
S.
government, as well as the relevant policies, procurement and distribution of the new crown antigen home self-test kit products.
plans and situations
.
Investors are advised to note that the relevant situations and purchases involved in the above content are not just for the company.
Do not misunderstand the content and wrongly infer the changes it will bring to the company's performance
.
The sales situation disclosed by the company in the previous announcement cannot represent the profit.
Because the profit is related to many factors such as raw material cost, sales expenses, management expenses and R&D expenses, it is impossible to calculate the profit situation from the sales amount.
The company's stock price is currently at a historical high.
The risk of a fall in the future cannot be ruled out
.
On the last trading day of 2021, Jiu'an Medical's stock price fell by the limit.
Even if it fell sharply, the company still ranked 4th on the increase list with its strong previous gains
.
Recently, Longshen Rongfa also hit the daily limit again, rising 140% in 9 trading days
.
On December 31, the company issued an announcement of serious abnormal fluctuations in stock trading and suspension of trading
.
According to the data, the main business of Longshen Rongfa is the research and development of pharmaceutical products, medical products, and health care products, and the production and sales of Chinese patent medicines, health food, and APIs
.
The main products Yuanhu Zhitong Dropping Pills, Suanzaoren Oil Dropping Pills, Berberine Tannic Acid Film and Qiwei Wenyang Capsules are all exclusive varieties
.
In the first three quarters of 2021, the company's revenue was 167 million yuan, a year-on-year decrease of 0.
75%; net profit loss was 8.
18 million yuan, a year-on-year increase of 35.
84%; gross profit margin was 29.
23%
.
.
On December 31, the company issued an announcement of serious abnormal fluctuations in stock trading and suspension of trading
.
According to the data, the main business of Longshen Rongfa is the research and development of pharmaceutical products, medical products, and health care products, and the production and sales of Chinese patent medicines, health food, and APIs
.
The main products Yuanhu Zhitong Dropping Pills, Suanzaoren Oil Dropping Pills, Berberine Tannic Acid Film and Qiwei Wenyang Capsules are all exclusive varieties
.
In the first three quarters of 2021, the company's revenue was 167 million yuan, a year-on-year decrease of 0.
75%; net profit loss was 8.
18 million yuan, a year-on-year increase of 35.
84%; gross profit margin was 29.
23%
.
Source: Oriental Fortune Network, company announcement
2021 is fleeting, and in the past year, A shares have set multiple records
.
In terms of pharmaceutical stocks, the Chinese medicine sector performed brightly on the last trading day of last year, rising by more than 5%, and more than 10 Chinese medicine stocks such as Taiji Group and Qianjin Pharmaceutical rose by the daily limit
.
As of the close on December 31, 2021, 14 pharmaceutical stocks including Mindray Medical, WuXi AppTec, Hengrui Medicine, and Pien Tze Huang have a market value of 100 billion yuan
.
Mindray Medical ranked as the "first brother" of pharmaceutical stocks, and BeiGene entered the top ten; Pien Tze Huang rose to the fourth place with a growth rate of more than 60%, and its market value reached a new high
.
Judging from the rise and fall, the market value of 48 companies including Guangyuyuan and Medicilon has doubled
.
It is worth mentioning that in 2019, there were only 5 pharmaceutical stocks with a market value of 100 billion yuan, which will surge to 11 in 2020
.
.
In terms of pharmaceutical stocks, the Chinese medicine sector performed brightly on the last trading day of last year, rising by more than 5%, and more than 10 Chinese medicine stocks such as Taiji Group and Qianjin Pharmaceutical rose by the daily limit
.
As of the close on December 31, 2021, 14 pharmaceutical stocks including Mindray Medical, WuXi AppTec, Hengrui Medicine, and Pien Tze Huang have a market value of 100 billion yuan
.
Mindray Medical ranked as the "first brother" of pharmaceutical stocks, and BeiGene entered the top ten; Pien Tze Huang rose to the fourth place with a growth rate of more than 60%, and its market value reached a new high
.
Judging from the rise and fall, the market value of 48 companies including Guangyuyuan and Medicilon has doubled
.
It is worth mentioning that in 2019, there were only 5 pharmaceutical stocks with a market value of 100 billion yuan, which will surge to 11 in 2020
.
The "first brother" of the pharmaceutical stocks flashed over 40 billion, and the Chinese medicine stocks went up and down
The "first brother" of the pharmaceutical stocks flashed over 40 billion, and the Chinese medicine stocks went up and down On the first day of the opening of the A-share market in 2022 (January 4th), Mindray Medical, the “first brother” of the pharmaceutical stock, suddenly crashed in the intraday market
.
According to the news, there are rumors in the market that Mindray Medical's performance did not meet expectations, and sales staff left in large numbers
.
In response, Mindray Medical responded that the company has not disclosed its 2021 annual report, so it cannot disclose performance-related situations
.
The company has not released any relevant information affecting the performance trend, and there has been no incident where the performance did not meet expectations and the sales staff left
.
.
According to the news, there are rumors in the market that Mindray Medical's performance did not meet expectations, and sales staff left in large numbers
.
In response, Mindray Medical responded that the company has not disclosed its 2021 annual report, so it cannot disclose performance-related situations
.
The company has not released any relevant information affecting the performance trend, and there has been no incident where the performance did not meet expectations and the sales staff left
.
According to the data, Mindray Medical's revenue in the first three quarters of 2021 was 19.
392 billion yuan, a year-on-year increase of 20.
72%; its net profit was 6.
663 billion yuan, a year-on-year increase of 24.
23%
.
As of the close on January 5, Mindray Medical's share price rose by more than 3%, with a market value of nearly 420 billion yuan
.
392 billion yuan, a year-on-year increase of 20.
72%; its net profit was 6.
663 billion yuan, a year-on-year increase of 24.
23%
.
As of the close on January 5, Mindray Medical's share price rose by more than 3%, with a market value of nearly 420 billion yuan
.
Note: Statistics as of the close of market on January 4, 2022
On the last trading day of 2021, the traditional Chinese medicine sector rose by more than 5%, and more than 10 traditional Chinese medicine stocks, including Zuoli Pharmaceutical, Taiji Group, Tongrentang, Jianmin Group, and Qianjin Pharmaceutical, reached the daily limit
.
On the first day of trading in 2022, although the three major indexes fell across the board, Chinese medicine stocks bucked the trend and strengthened.
As of the close of the day, more than 10 Chinese medicine stocks, including Taiji Group, Qianjin Pharmaceutical, and Yisheng Pharmaceutical, continued to trade at their daily limit.
Among them, Tongrentang and Jianmin Group wait for new highs
.
Judging from the news, recently, the National Medical Security Administration and the State Administration of Traditional Chinese Medicine issued the "Guiding Opinions on Medical Insurance Supporting the Inheritance and Innovation of Traditional Chinese Medicine"; Approved to build a national comprehensive reform demonstration area of traditional Chinese medicine
.
.
On the first day of trading in 2022, although the three major indexes fell across the board, Chinese medicine stocks bucked the trend and strengthened.
As of the close of the day, more than 10 Chinese medicine stocks, including Taiji Group, Qianjin Pharmaceutical, and Yisheng Pharmaceutical, continued to trade at their daily limit.
Among them, Tongrentang and Jianmin Group wait for new highs
.
Judging from the news, recently, the National Medical Security Administration and the State Administration of Traditional Chinese Medicine issued the "Guiding Opinions on Medical Insurance Supporting the Inheritance and Innovation of Traditional Chinese Medicine"; Approved to build a national comprehensive reform demonstration area of traditional Chinese medicine
.
On January 1, 2022, Taiji Group released the "14th Five-Year" Strategic Planning Outline (2021-2025), which clarified that the main line of intelligent manufacturing of modern traditional Chinese medicine, supplemented by the characteristic chemical drugs of anesthesia and regional commercial leaders the strategic direction of the line
.
The core main line gives full play to the brand influence of the well-known trademark of "Taiji (TAIJI)" and the century-old "Tongjunge" brand, fully taps the market value of traditional Chinese medicine, brand products, and classic prescriptions, and creates a variety of products with technological innovation, intelligent manufacturing, etc.
Advantages of modern Chinese medicine
.
The parallel auxiliary line is to build a chemical and biological drug production base featuring narcotics and to build a leading pharmaceutical business enterprise in Sichuan and Chongqing
.
The company unswervingly focuses on the main business of medicine and health, and on the premise of steady improvement in basic management, realizes the "achievement of scientific research and development capabilities, source control, production intelligence, terminal connection and marketing breakthrough, and creating new models, new formats and new concepts.
" The large-scale pharmaceutical base in the “Chongqing Shuangcheng Circle” has become the strategic growth pole of Sinopharm Group in western China
.
Through endogenous development and external expansion, the company strives to achieve a revenue of 50 billion yuan at the end of the "14th Five-Year Plan", and strives to become a world-class Chinese medicine enterprise
.
.
The core main line gives full play to the brand influence of the well-known trademark of "Taiji (TAIJI)" and the century-old "Tongjunge" brand, fully taps the market value of traditional Chinese medicine, brand products, and classic prescriptions, and creates a variety of products with technological innovation, intelligent manufacturing, etc.
Advantages of modern Chinese medicine
.
The parallel auxiliary line is to build a chemical and biological drug production base featuring narcotics and to build a leading pharmaceutical business enterprise in Sichuan and Chongqing
.
The company unswervingly focuses on the main business of medicine and health, and on the premise of steady improvement in basic management, realizes the "achievement of scientific research and development capabilities, source control, production intelligence, terminal connection and marketing breakthrough, and creating new models, new formats and new concepts.
" The large-scale pharmaceutical base in the “Chongqing Shuangcheng Circle” has become the strategic growth pole of Sinopharm Group in western China
.
Through endogenous development and external expansion, the company strives to achieve a revenue of 50 billion yuan at the end of the "14th Five-Year Plan", and strives to become a world-class Chinese medicine enterprise
.
Looking back on last year, the pharmaceutical sector as a whole showed a first rise and then a decline.
Since November, the sector index has started to repair again, and since late December, the traditional Chinese medicine sector has continued to strengthen
.
The brokerage analysis pointed out that the country has successively introduced relevant policies for the development of the Chinese medicine industry in recent years, and incorporated Chinese medicine into the national development plan.
Good for the long-term development of the industry
.
Since November, the sector index has started to repair again, and since late December, the traditional Chinese medicine sector has continued to strengthen
.
The brokerage analysis pointed out that the country has successively introduced relevant policies for the development of the Chinese medicine industry in recent years, and incorporated Chinese medicine into the national development plan.
Good for the long-term development of the industry
.
Top 20 pharmaceutical stocks
Note: Statistics as of the close of business on December 31, 2021
According to statistics, 14 pharmaceutical stocks, including Mindray Medical, WuXi AppTec, Hengrui Pharmaceutical, Pien Tze Huang, and BeiGene, are worth 100 billion yuan
.
Mindray Medical was listed as the "first brother" in pharmaceutical stocks, and BeiGene entered the top ten as the first "A+H+N" listed pharmaceutical company
.
Pien Tze Huang ranked 4th with a growth rate of more than 60%, up 3 places compared with 2020, and is also the fastest growing company in the TOP20
.
In addition, the market value growth rate of Wantai Bio and Huadong Medicine both exceeded 50%
.
It is worth mentioning that in 2019, there were only 5 pharmaceutical stocks with a market value of 100 billion yuan, which will surge to 11 in 2020
.
.
Mindray Medical was listed as the "first brother" in pharmaceutical stocks, and BeiGene entered the top ten as the first "A+H+N" listed pharmaceutical company
.
Pien Tze Huang ranked 4th with a growth rate of more than 60%, up 3 places compared with 2020, and is also the fastest growing company in the TOP20
.
In addition, the market value growth rate of Wantai Bio and Huadong Medicine both exceeded 50%
.
It is worth mentioning that in 2019, there were only 5 pharmaceutical stocks with a market value of 100 billion yuan, which will surge to 11 in 2020
.
The strongest "demon stock" in the fourth quarter was born! Guangyuyuan, Jianmin.
.
.
The market value of 48 companies doubled
.
.
The market value of 48 companies doubled
Pharmaceutical stocks that rose more than 100%
Note: Statistics as of the close of business on December 31, 2021
From the perspective of changes, the market value of 48 companies including Guangyuyuan, Medicilon, Jianmin Group, Shuyu Pingmin, and Ha Sanlian has doubled.
Among them, Jiu'an Medical has achieved 24 daily limits in 34 trading days, becoming the fourth The strongest "demon stock" in the quarter; Longshen Rongfa soared 140% in 9 trading days and was suspended for verification
.
Among them, Jiu'an Medical has achieved 24 daily limits in 34 trading days, becoming the fourth The strongest "demon stock" in the quarter; Longshen Rongfa soared 140% in 9 trading days and was suspended for verification
.
Jiu'an Medical started the rising mode in mid-November 2021.
From November 15th to now, it has gained 24 daily limits in 34 trading days, with an increase of more than 400% in 2021
.
During this period, the company issued a number of abnormal stock trading fluctuations and risk warning announcements, letters of concern, and supervision letters, but this did not suppress the continuous rise of Jiu'an Medical's stock price
.
On December 30, Jiu’an Medical released the company’s stock trading risk warning announcement, saying that the company mentioned in the previous announcement the epidemic prevention-related plans issued by the U.
S.
government, as well as the relevant policies, procurement and distribution of the new crown antigen home self-test kit products.
plans and situations
.
Investors are advised to note that the relevant situations and purchases involved in the above content are not just for the company.
Do not misunderstand the content and wrongly infer the changes it will bring to the company's performance
.
The sales situation disclosed by the company in the previous announcement cannot represent the profit.
Because the profit is related to many factors such as raw material cost, sales expenses, management expenses and R&D expenses, it is impossible to calculate the profit situation from the sales amount.
The company's stock price is currently at a historical high.
The risk of a fall in the future cannot be ruled out
.
On the last trading day of 2021, Jiu'an Medical's stock price fell by the limit.
Even if it fell sharply, the company still ranked 4th on the increase list with its strong previous gains
.
From November 15th to now, it has gained 24 daily limits in 34 trading days, with an increase of more than 400% in 2021
.
During this period, the company issued a number of abnormal stock trading fluctuations and risk warning announcements, letters of concern, and supervision letters, but this did not suppress the continuous rise of Jiu'an Medical's stock price
.
On December 30, Jiu’an Medical released the company’s stock trading risk warning announcement, saying that the company mentioned in the previous announcement the epidemic prevention-related plans issued by the U.
S.
government, as well as the relevant policies, procurement and distribution of the new crown antigen home self-test kit products.
plans and situations
.
Investors are advised to note that the relevant situations and purchases involved in the above content are not just for the company.
Do not misunderstand the content and wrongly infer the changes it will bring to the company's performance
.
The sales situation disclosed by the company in the previous announcement cannot represent the profit.
Because the profit is related to many factors such as raw material cost, sales expenses, management expenses and R&D expenses, it is impossible to calculate the profit situation from the sales amount.
The company's stock price is currently at a historical high.
The risk of a fall in the future cannot be ruled out
.
On the last trading day of 2021, Jiu'an Medical's stock price fell by the limit.
Even if it fell sharply, the company still ranked 4th on the increase list with its strong previous gains
.
Recently, Longshen Rongfa also hit the daily limit again, rising 140% in 9 trading days
.
On December 31, the company issued an announcement of serious abnormal fluctuations in stock trading and suspension of trading
.
According to the data, the main business of Longshen Rongfa is the research and development of pharmaceutical products, medical products, and health care products, and the production and sales of Chinese patent medicines, health food, and APIs
.
The main products Yuanhu Zhitong Dropping Pills, Suanzaoren Oil Dropping Pills, Berberine Tannic Acid Film and Qiwei Wenyang Capsules are all exclusive varieties
.
In the first three quarters of 2021, the company's revenue was 167 million yuan, a year-on-year decrease of 0.
75%; net profit loss was 8.
18 million yuan, a year-on-year increase of 35.
84%; gross profit margin was 29.
23%
.
.
On December 31, the company issued an announcement of serious abnormal fluctuations in stock trading and suspension of trading
.
According to the data, the main business of Longshen Rongfa is the research and development of pharmaceutical products, medical products, and health care products, and the production and sales of Chinese patent medicines, health food, and APIs
.
The main products Yuanhu Zhitong Dropping Pills, Suanzaoren Oil Dropping Pills, Berberine Tannic Acid Film and Qiwei Wenyang Capsules are all exclusive varieties
.
In the first three quarters of 2021, the company's revenue was 167 million yuan, a year-on-year decrease of 0.
75%; net profit loss was 8.
18 million yuan, a year-on-year increase of 35.
84%; gross profit margin was 29.
23%
.
Source: Oriental Fortune Network, company announcement
